A Phase IIa randomized clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle vaccine in adults 60–85 years of age

IVX-A12 was well tolerated and induced RSV- and hMPV-specific antibody responses in adults 60-85 years of age. This trial demonstrated the feasibility of an RSV/hMPV combination vaccine.